Aligos Therapeutics Inc. (ALGS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALGS Stock Price Chart Interactive Chart >
ALGS Price/Volume Stats
| Current price | $1.25 | 52-week high | $34.31 |
| Prev. close | $1.19 | 52-week low | $1.03 |
| Day low | $1.11 | Volume | 246,000 |
| Day high | $1.27 | Avg. volume | 485,656 |
| 50-day MA | $1.60 | Dividend yield | N/A |
| 200-day MA | $8.64 | Market Cap | 53.37M |
Aligos Therapeutics Inc. (ALGS) Company Bio
Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Latest ALGS News From Around the Web
Below are the latest news stories about Aligos Therapeutics Inc that investors may wish to consider to help them evaluate ALGS as an investment opportunity.
Leerink Partners Thinks Aligos Therapeutics’ Stock is Going to RecoverIn a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on Aligos Therapeutics (ALGS – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $2.64, close to its 52-week low of $2.47. According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -34.1% and a 18.8% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aligos Therapeutics with a $14.67 average price target. |
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say YesDrug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. |
Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present in a fireside chat format at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 12:00 pm ET. Both the presenta |
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete First chronic hepatitis B patient dosed in initial cohort, each of which will be administered 7 subcutaneous doses over 29 days SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the first |
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
ALGS Price Returns
| 1-mo | 1.63% |
| 3-mo | -49.39% |
| 6-mo | -91.77% |
| 1-year | -95.52% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -89.47% |
| 2021 | -57.07% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...